Additionally, with the discovery of tumor biomarkers, such as alpha-fetoprotein, prostate specific antigen (PSA) and carcinoembryonic antigen (CEA), the feasibility of analysis in oncology has been enhanced [5]. This evidence concerns the gene CEACAM5 and neoplasm.